At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 213 enrolled
Drug / intervention
axitinib +2 moredrug
Likely dose
axitinib 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-blind Phase 2 Study Of Axitinib (Ag-013736) With Or Without Dose Titration In Patients With Metastatic Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating axitinib for Carcinoma, Renal Cell. Completed, enrolled 213 participants across 65 sites in 6 countries.
Detailed Summary
Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesCzechia, Germany, Japan, Russia, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2009
Enrollment StartAug 2009
Primary CompletionOct 2012
Study CompletionFeb 2016
TodayJul 2026
First PostedFeb 4, 2009
Enrollment StartAug 1, 2009
Primary CompletionOct 1, 2012
Study CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 17.4 years ago
Interventions
axitinibdrug
axitinib 5mg BID (open-label) + axitinib dose titration (blinded)
axitinibdrug
axitinib 5mg BID (open-label) + placebo dose titration (blinded)
axitinibdrug
axitinib 5mg BID (open-label)